UpdatesPlus - Immunology



Description

The transition of laboratory indexes is unknown for long-term (2-year) upadacitinib treatment in atopic dermatitis (AD). To assess the 96-week real-world effects of upadacitinib on the transition of immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) in Japanese patients with AD, stratified by age groups (

Source URL:

http://www.ncbi.nlm.nih.gov/pubmed/?term=40300847